Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174792 | 1.00 | AXL (0.41) | AXLAURKAPARP1GPR84KDM4E | |
| SCHEMBL30631993 | 0.77 | PDPK1 (0.48) | AXLAURKAPARP1GPR84KDM4E | |
| SCHEMBL1495296 | 0.77 | PDPK1 (0.48) | AXLAURKAPARP1GPR84KDM4E | |
| SCHEMBL174642 | 0.77 | PDPK1 (0.48) | AXLAURKAPARP1GPR84KDM4E | |
| SCHEMBL1639471 | 0.75 | AXL (0.41) | AXLAURKAPARP1GPR84KDM4E | |
| SCHEMBL1573790 | 0.75 | AXL (0.41) | AXLAURKAPARP1GPR84KDM4E | |
| SCHEMBL1593049 | 0.75 | AXL (0.50) | AXLAURKAPARP1GPR84KDM4E | |
| SCHEMBL30204060 | 0.75 | AXL (0.50) | AXLAURKAPARP1GPR84KDM4E | |
| SCHEMBL1343940 | 0.75 | GPR84 (0.44) | AXLAURKAPARP1GPR84KDM4E | |
| SCHEMBL253764 | 0.75 | NPC1 (0.43) | AXLAURKAPARP1GPR84KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186408-A1 | TREATMENT OF PHARMACORESISTANT EPILEPSY | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-06-12 | — | — | US | disclosed |
| CN-119431362-A | Substituted heteroaryl carboxylic acid compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2025-02-14 | — | — | CN | disclosed |
| CN-119219630-A | 1H-pyrazolo [3,4-B ] pyridine-3-carbonitrile crystal form A and preparation method thereof | 合肥菁科生物科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| EP-4476224-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2024-12-18 | — | — | EP | disclosed |
| CN-118679163-A | Bicyclic heteroaryl compounds and uses thereof | 上海奕拓医药科技有限责任公司 | 2024-09-20 | — | — | CN | disclosed |
| WO-2024092222-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024006379-A1 | METHODS AND COMPOUNDS FOR INHIBITING MKK7 ENZYMES | AXONIS THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| EP-4196480-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND USE THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2023-06-21 | — | — | EP | disclosed |
| CN-115956080-A | Bicyclic compounds, compositions containing them and their use | 贝达药业股份有限公司 | 2023-04-11 | — | — | CN | disclosed |
| WO-2022187520-A1 | SUBSTITUTED 3-PIPERIDINYL-PYRAZOLO[3,4-B]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Ikena Oncology, Inc. (US) | 2022-09-09 | — | — | WO | disclosed |
| CN-107624112-B | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | 美国政府健康及人类服务部 | 2022-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186408-A1 | TREATMENT OF PHARMACORESISTANT EPILEPSY | CNR1, CNR2, CYP2J2 | AXL 4577/4885AURKA 4173/4885PARP1 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.